CareDx Stock News

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinica

Acquisition will build on CareDx's digital capabilities and continue deepening the moat with transplant centers Acquisition will build on CareDx's digital capabilities and continue deepening the moat

CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transpl

CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang CareDx wins a 2-year competitive tender with the French National Blood Service, Établi

CareDx offers organ testing products that are non-invasive alternatives to more invasive traditional tests. The organ transplant market is expected to grow through 2027, creating a tailwind for CareDx

Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.

We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.

Partners with large transplant coalition to expand access to lifesaving medications for kidney transplant patients Partners with large transplant coalition to expand access to lifesaving medications f

As of late, it has definitely been a great time to be an investor in CareDx (CDNA).

The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinic

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinic

Research from Johns Hopkins , U niversity of Maryland, and Cedars Sinai Shows AlloSure May Signal BK Virus Progression in Transplant Patients

CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacific Northwest Virtual Kidney Walk CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacific Northw